Radiation Therapy in the Treatment of Small Cell Lung Cancer

Guler Yavas* and Cagdas Yavas

Department of Radiation Oncology, Selcuk University, Turkey

Abstract
Small Cell Lung Cancer (SCLC) represents between 13-15% of all lung cancers; however is the fifth leading cause of cancer death worldwide. SCLC prognosis remains poor despite improvements in diagnosis and treatment over the last 30 years. Patients with SCLC are typically divided into those with Limited Stage (LS) versus Extensive Stage (ES). LS disease is treated with concurrent chemotherapy and thoracic radiotherapy followed by Prophylactic Cranial Irradiation (PCI). For patients with ES-SCLC current approach is using combination chemotherapy with a platinum-based regimen. All the patients who demonstrate response to chemotherapy and have a good performance status with ES-SCLC should receive PCI. The role of thoracic radiotherapy in ES-SCLC was to palliate disease related symptoms. However the recent reports evaluating the role of thoracic radiotherapy in ES-SCLC, have demonstrated that consolidative thoracic radiotherapy is beneficial for selected patients with ES-SCLC who respond to chemotherapy but in whom there is evidence of residual disease within the chest. Recent technical advances in radiation treatment including intensity-modulated radiotherapy, and stereotactic radiotherapy allowed enhancing precise delivery as well as minimizing the radiation related toxicities.

Keywords
Small cell lung cancer, Radiotherapy, Prophylactic cranial irradiation, Limited stage, Extensive stage

Introduction
Lung cancer is the leading cause of cancer-related death in the world, and the second in incidence in both genders; nevertheless, the Small Cell Lung Cancer (SCLC) subtype covers only 13-15% of total lung cancer diagnosis [1]. A decrease in SCLC’s incidence has been seen in the last 20 years, probably related to the decrease in tobacco use in occidental countries, since SCLC occurs predominantly in smokers, as well as to the recognition of other subtype: large cell neuroendocrine carcinoma, which before 1990 was considered to be SCLC [1,2].

SCLC is a highly aggressive, undifferentiated neoplasia that originates from the precursors of neuroendocrine cells. SCLC is distinguished from Non-Small Cell Lung Cancer (NSCLC) by its rapid doubling time, high growth fraction, and the early development of widespread metastases [3]. Approximately two-thirds of SCLC patients have clinical evidence of metastasis at diagnosis; most of the remaining third have clinical evidence of extensive involvement of hilar, mediastinal, and sometimes supraclavicular lymph nodes. Although SCLC is initially highly responsive to chemotherapy and radiotherapy, the majority of patients will relapse with broadly resistant disease within few months to a year from initial therapy.

A simple staging system for SCLC was introduced by the Veterans Administration Lung Study Group (VALG) in 1957 for randomized trials in inoperable lung cancer patients [4]. This system classifies patients into the two categories of limited and extensive disease lung cancer, depending in principal on whether all known tumors could be treated within a single radiotherapy portal or not. Limited Stage-Small Cell Lung Cancer (LS-SCLC) is defined as disease that is limited to the ipsilateral hemothorax and regional lymph nodes and can be encompassed in a safe radiotherapy field. However the majority of patients with SCLC have Extensive Stage (ES) disease, with tumor that includes distant metastases, malignant pericardial or pleural effusions, and/or contralateral supraclavicular or contralateral hilar lymph node involvement. VALG staging system is generally ac-
cepted in SCLC in clinical practice and is usually sufficient for treatment decisions regarding local therapy and carries prognostic information independent whether chemotherapy is used or not [5].

Radiation Therapy (RT) plays a fundamental role in the management and care of patients with SCLC [6]. The current standard approach for LS-SCLC consist of combination chemotherapy with four cycles of a platinum-based regimen in conjunction with concurrent thoracic RT, followed by Prophylactic Cranial Irradiation (PCI) for patients who demonstrate an objective therapeutic response. The addition of thoracic RT and PCI improves both local control and overall survival [6,7]. The standard care for ES-SCLC was combination chemotherapy with a platinum-based regimen. The role of RT in ES-SCLC was only for palliative purpose historically. However in a phase III trial, Slotman and colleagues demonstrated that PCI increases overall survival in patients with ES-SCLC who have response to chemotherapy [8]. The importance of thoracic RT in ES-SCLC was demonstrated in two phase III randomized trials [9,10]. Both of these studies suggested that consolidation chest RT, after chemotherapy for ES-SCLC improved Local Control (LC) which may influence Overall Survival (OS). Therefore for patients with ES-SCLC who have had a favorable response to chemotherapy but in whom there is evidence of residual disease within the chest identified on Computed Tomography (CT), thoracic RT should be considered. The purpose of the present review is to report the role of the RT in the management of SCLC by the light of the novel publications.

**Limited stage disease**

The role of thoracic radiotherapy in the limited stage disease: Approximately only 5% of SCLC patients present as T1-2N0-1 M0 disease; and these have shown to have a more favorable long term prognosis, with a 5-year OS of 50% [11]. LS-SCLC is a potentially curable disease when it is aggressively and rapidly treated with concomitant chemoradiotherapy [1]. Although the current guidelines of the National Comprehensive Cancer Network (NCCN) [12], and the American College of Chest Physicians (ACCP) [13] are not identical; both recommend that only patients with clinical stage I disease (T1-2 N0) should be considered for surgery. It has been demonstrated in a retrospective studies that in patients with stage I SCLC (T1-2 N0 M0) that undergo lobectomy, and with confirmed lack of mediastinal and supraclavicular involvement, long-term OS is 40-60% [14,15]. On the other hand, it was demonstrated that patients with node involvement do not benefit from excisional treatment; and therefore this modality should not be offered to patients with N1-3 disease [15]. It is mandatory to offer four cycles of cisplatin-based adjuvant chemotherapy after lobectomy. In cases where pathologic analysis of mediastinal nodes sampling is positive for malignant disease (N1 or N2) and a complete lymphadenectomy has not been performed, postoperative mediastinal RT should be considered [1].

In a randomized study Murray and colleagues demonstrated that thoracic RT was superior to surgery [16]. However this study was performed in 1960; and active chemotherapeutic agents had not been discovered yet and; long-term survivors were few. In 1980 the active chemotherapeutic agents against SCLC was introduced. In that years there was a trend suggesting that RT might not be needed in SCLC [7,17]. However, subsequent studies demonstrated high rates of local recurrence without thoracic RT, thus supporting its role in optimal care of LS-SCLC [17]. Two large meta-analyses have suggested that the addition of thoracic RT provides absolute survival benefit of 5% at 2 and 3 years, respectively for patients treated with chemo-radiotherapy [18,19]. One meta-analysis, which included 11 randomized studies, found that the addition of thoracic RT was associated with an absolute improvement in local control of 23 percent (two-year local control rate 47 versus 24 percent) [19]. Another meta-analysis of 13 randomized trials (including the same 11) found that the use of combined chemotherapy and thoracic RT resulted in an absolute survival benefit of 5.4 percent at three years [18]. The survival benefit associated with the use of thoracic RT outside of clinical trials was confirmed in a more recent review from the National Cancer Data Base [20].

The optimal dose and fractionation scheme for concurrent chemoradiation for LS-SCLC is an area of active investigation. SCLC is highly radiosensitive suggesting that hyperfractionation could be employed to reduce late normal tissue toxicity. The current standard of care for the dose and fractionation of thoracic RT is based on the randomized phase III Intergroup 0096 study [21], which compared 45 Gy/1.8 Gy per fraction in 25 fractions over 5 weeks once-daily to 45 Gy/1.5 Gy per fraction BID in 30 fractions over 3 weeks. In both treatment methods thoracic RT started with the first cycle of four planned cycles of concurrent cisplatin + etoposide (PE). Twice-daily treatment beginning with the first cycle of chemotherapy significantly improved survival as compared with concurrent once-daily radiotherapy (P = 0.04 by the log-rank test). After a median follow-up of almost 8 years, the median survival was 19 months for the once-daily group and 23 months for the twice-daily group. The rate of local failure was 36% in the group receiving twice-daily RT (P = 0.06). In fact, twice-daily regimen has been poorly adopted by physicians. Therefore the most active area of clinical research in thoracic RT in LS-SCLC concerns its optimal total dose and fractionation [6]. Two contemporary phase III randomized trials are addressing the question of whether a higher total dose of thoracic RT will result in an improvement in OS: CONVERT (concurrent once daily versus twice daily radiotherapy) [22]; and North America (CALGB 30610/RTOG 0538) [23].
primary end-point of both studies is an improvement in OS. In CONVERT trial patients were randomized to 45 Gy/1.5 Gy BID in 30 fractions or to 66 Gy in 33 once-daily fractions, both starting with the second cycle of PE [22]. In North America trial the standard arm of 45 Gy/1.5 Gy BID was compared with either 70 Gy/2 Gy once-daily over 7 weeks or 61.2 Gy/1.8 Gy once-daily over 16 days followed by 1.8 Gy twice-daily for 9 days [23]. All schedules had RT administered with concurrent PE starting at cycle 1 or 2. In March 2013 61.2 Gy arm was closed after a series of planned interim analyses by the Data Safety and Monitory Board to determine the feasibility of dropping one of the experimental arms. Because in 61.2 Gy arm there were three on-study deaths compared to the 70 Gy arm; which had none [6].

Hyperfractionated thoracic RT has also been delivered as a split course treatment with alternating regimen of chemotherapy and thoracic RT. In a pilot study by the Eastern Cooperative Oncology Group (ECOG), thoracic RT consisting of 1.5 Gy given twice daily over five continuous days was delivered after the first, second, and third cycles of etoposide and cisplatin (EP) chemotherapy [24]. The two-year progression-free survival for this series was 47 percent. The Groupe Lyonnais d’Oncologique Thoracique reported the results of a similar hyperfractionated thoracic RT schedule alternating with chemotherapy in the treatment of 76 patients [25]. The median survival for this group was 14 months, and the one-year disease-free survival was 42 percent. In summary, the optimal dose and fractionation approach for SCLC remains to be defined. An ongoing intergroup effort (CALGB 30610, RTOG 0538, NCT00632853) seeks to determine the optimal radiation schedule.

Historically, thoracic RT treatment volumes included all gross disease present at the time of initial diagnosis (pre-chemotherapy volume), as well as prophylactic inclusion of adjacent uninvolved nodal regions. However the Southwest Oncology Group (SWOG) performed a randomized trial, in which 191 patients with LS-SCLC who had a partial response or stable disease following induction chemotherapy were randomly assigned to thoracic RT fields that included either the prechemotherapy or the postchemotherapy tumor volumes [26]. There weren’t any statistically significant differences with respect to the patterns of failure or median survival between the two regimens. There was no apparent difference in severe drug-related toxicity or severe radiation pneumonitis between the thoracic RT groups. However, the frequency of severe complications related to myelosuppression was higher for patients treated with wide field thoracic RT. SWOG trial is the only randomized trial to date addressing the specific question of treatment volume. Despite some uncertainty, the use of limited field thoracic RT is the current standard of care. Specifically, the treatment volume should include all gross disease present at the time of radiation planning (postchemotherapy volume), and all nodal regions involved at the time of initial diagnosis (prechemotherapy volume). PET scans should be obtained for staging if RT is planned for patients with suspected LS-SCLC.

Thoracic RT is routinely delivered early and concurrent with, rather than late or sequential to chemotherapy if patient’s condition is appropriate. Because three major meta-analyses showed that the early administration of thoracic RT is associated with improved survival [27-29]. The addition of thoracic RT integrated with EP chemotherapy during cycle 1 or 2 is the current standard of care for patients with LS-SCLC. Although there are conflicting data regarding the optimal timing of thoracic RT relative to chemotherapy, the studies that employed standard EP chemotherapy delivered with minimal dose reduction all showed a clear benefit for early thoracic RT.

The role of prophylactic cranial radiotherapy in the limited stage disease: The value of PCI was demonstrated in a meta-analysis of seven randomized trials that included 987 patients who achieved a complete remission with chemotherapy and received PCI between 1977 and 1995 [30]. In this meta-analysis Auperin and colleagues reported that PCI yields a 25.3% decreased incidence of brain metastases at 3 years (P < 0.001) and that overall and disease-free survivals are increased in PCI group by 5.4% (P = 0.01) and 8.8% (P < 0.001) respectively at 3 years. After the publication of this meta-analysis PCI became standard of care in LS-SCLC patients who has complete response to concurrent chemo-radiotherapy.

In patients with LS-SCLC who have a good response to initial therapy, PCI both decreases incidence of brain metastases and increases OS [30,31]. The effectiveness of PCI in patients with limited stage SCLC has been established by the results from numerous clinical trials. NCCN recommends PCI for all patients with LS-SCLC who have a good response to initial therapy and have good performance status [15].

Higher doses of radiation are associated with better control of brain metastases, although this benefit must be weighed against the risks of toxicity. Indirect evidence supporting the efficacy of higher doses of radiation in reducing brain metastases comes from the initial meta-analysis that established the efficacy of PCI, in which the dose of radiation was broken down into four categories (8 Gy, 24 to 25 Gy, 30 Gy, and 36 to 40 Gy) [30]. A statistically significant trend for improved control of brain metastases was observed with increasing total doses of radiation. The most extensive data on the impact of radiation dose come from a multinational phase III trial (PCI 99-01) in which patients receiving a dose of 36 Gy had a higher mortality and higher neurotoxicity compared to patients treated with 25 Gy [32,33]. The preferred dose for PCI to the whole brain is 25 Gy in 10 daily fractions [15]. Thirty Gy in 2 Gy fractions is
also an acceptable regimen. PCI is not given during chemotherapy to decrease the risk of leukoencephalopathy [34].

**Extensive stage disease**

The role of thoracic radiotherapy in the extensive stage disease: The majority of patients with SCLC have extensive stage disease, with tumor that includes distant metastases, malignant pericardial or pleural effusions, and/or contralateral supraclavicular or contralateral hilar lymph node involvement. Systemic therapy is the essential element in the treatment of patients with ES-SCLC with good performance status; however thoracic RT may play a role in selected patients. Thoracic RT has typically been used in ES-SCLC primarily for symptom palliation [7]. Based on the results of a randomized trial by Jeremic, et al. [9], the addition of sequential thoracic RT may be considered in select patients with low-bulk metastatic disease who have a complete or near complete response after initial chemotherapy. This study randomized ES-SCLC patients who had received three induction cycles of PE and shown a partial response at distant sites and at least a partial response in the chest to either hyperfractionated thoracic RT (54 Gy in 36 fractions/twice-daily fractions over 18 days) plus daily low-dose chemotherapy or to four additional cycles of PE without RT. PCI was offered to responders in both groups. Thoracic RT significantly increased overall survival compared with chemotherapy (median 17 versus 11 months, five-year survival rate 9% versus 3.7%; p = 0.041).

In a European multicenter trial (Dutch Crest Trial), patients with ES-SCLC were initially treated with four to six cycles of platinum-based chemotherapy [10]. Following this, 498 patients with at least some response to chemotherapy were randomly assigned to thoracic RT (30 Gy in 10 fractions) plus PCI or PCI without thoracic RT. The primary endpoint of the trial was overall survival. The authors reported that the addition of sequential thoracic RT did not improve the primary end point of 1-year OS (33% vs. 28%, p = 0.066). However, in a secondary analysis, the survival curves diverged after longer follow-up, and subsequent survival was significantly better for those receiving thoracic RT (two-year overall survival rate 13% versus 3%, p = 0.004). The findings of Dutch Crest Study [10] and the earlier Jeremic study [9] should encourage clinicians to consider the option of thoracic RT.

Thoracic RT in ES-SCLC is currently the subject of at least two prospective trials in North America. The first trial is Radiation Therapy and Oncology Group (RTOG) 0937. RTOG 0937 is a randomized phase II study in patients with ES-SCLC who have more than three extra-thoracic sites of disease; patients are randomized to receive PCI alone versus PCI and consolidative thoracic RT (45 Gy in 30 fractions/twice-daily), after chemotherapy [35]. The second trial is the Chest Irradiation in Extensive Stage Small Cell Lung Cancer (CREST) trial conducted by Dutch Lung Cancer Study Group. In this trial the patients with ES-SCLC who responded to chemotherapy are randomized to thoracic RT (30 Gy/10 fraction) and PCI versus PCI. The results of these trials will help to clarify the role of thoracic RT in ES-SCLC patients.

The role of prophylactic cranial radiotherapy in the extensive stage disease: PCI decreases the incidence of symptomatic brain metastases in patients with ES-SCLC who have a response to systemic chemotherapy, although its effect on OS is uncertain. In the previously noted meta-analysis by Auperin, et al. [30], it is of interest that 15% of patients who received PCI were noted to have ES-SCLC, and it was found that for this subgroup, the benefit associated with PCI was of same magnitude as the limited disease subgroup [6].

PCI in ES-SCLC has been studied in two randomized multicenter trials: The first trial is a phase III randomized trial conducted by the European Organization for Research and Treatment of Cancer (EORTC), all patients initially received four to six cycles of chemotherapy [8]. At the completion of the initial chemotherapy patients with any degree of response after standard first-line chemotherapy randomized to PCI versus observation. Patients were not routinely imaged for the presence or absence of brain metastases after chemotherapy and prior to PCI. The primary objective of the study was the prevention of symptomatic brain metastases. At 1 year, the PCI patients were found to have a significantly lower rate of symptomatic brain metastases (15% vs. 40%, p < 0.001). There were improvements in 1-year (27% vs. 13%) and median (6.7 vs. 5.4 months, p = 0.003) survivals. In this study RT doses and schedules ranged from 20 Gy in 5 fractions to 30 Gy in 12 fractions.

Because in the first trial conducted by Slotman, et al. the patients did not have brain imaging prior to PCI, some authors have questioned whether the survival benefits seen with the addition of PCI could have come from an imbalance in the treatment arms such as that those not receiving PCI may have had more “undeclared” subclinical brain metastases which when left untreated would have compromised survival [6]. Therefore the second trial was conducted from Japan. In Japanese trial 224 ES-SCLC patients who had at least some response to their initial chemotherapy were randomly assigned to PCI (25 Gy/10 fractions) or no PCI [36]. Prior to randomization, patients underwent Magnetic Resonance Imaging (MRI) of the brain to rule out occult metastases. The primary endpoint of this trial was OS. Secondary endpoints included the incidence of brain metastases and progression-free survival. Preliminary results were presented at the 2014 American Society of Clinical
The meta-analysis suggested that the incidence of brain metastases might be reduced with higher PCI doses. Indeed through an indirect comparison of the trials, the estimated reduction in brain metastases with PCI was 24, 48, 68 and 73% with a total dose of 8, 24-25, 30 and 36-40 Gy, respectively [30]. Therefore the PCI Collaborative Group launched a randomized phase III study of 720 SCLC patients who had a complete response to the first-line chemotherapy. The PCI doses were standard dose with 25 Gy in 10 fractions or high-dose with either 36 Gy in 18 fractions or 24 Gy in 1.5 Gy twice daily fractions [32]. Toxicities and treatment delivery were not different between two arms.

After the phase III study conducted by Slotman, et al. PCI was extended to patients with ED-SCLC [8]. However, a Japanese phase III study failed to confirm the benefit of PCI for patients with ED SCLC [36]. All studies have demonstrated the effectiveness of PCI for preventing brain metastasis, this is not in doubt, but PCI seems to have a limited influence on OS. However the results of these trials provide strong evidence that PCI can decrease the incidence of symptomatic brain metastases. The impact of PCI on OS in patients with ES-SCLC who respond to chemotherapy remains uncertain. Thus PCI remains a consideration for ES-SCLC patients demonstrating objective and clinical benefits from their systemic therapies. The preferred dose for PCI to the whole brain is 25 Gy in 10 fractions [15]. Thirty Gy in 15 fractions is also an acceptable regimen. A short course (20 Gy in 5 fractions) may be appropriate in selected patients with ES-SCLC [15].

**Palliative radiotherapy in small cell lung cancer patients**

Palliative, or supportive care, is aimed at relieving symptoms and improving a person’s quality of life. Patients with metastatic SCLC often benefit from procedures to help with problems caused by the cancer. When delivered with palliative intent, RT can help to alleviate a multitude of symptoms related to advanced cancer. In general, time to symptom relief is measured in weeks to months after the completion of RT.

Brain metastases are very common in SCLC patients. The primary approaches to the treatment of brain metastases include surgery, Stereotactic Radio Surgery (SRS), and Whole Brain Radiation Therapy (WBRT). WBRT should be applied in case of brain metastases in SCLC patients. The most commonly used regimen is a total dose of 30 Gy in 10 daily fractions of 3 Gy. The decision in an individual case depends upon the severity of neurologic symptoms, the extent of systemic disease, and physician preference.

SRS delivers single or very limited number of high doses to a radiographically discrete treatment volume by using multiple convergent beams. This results in a rapid fall-off of dose at the edge of the target volume and a clinically insignificant dose to adjacent normal tissue. High energy x-rays produced by linear accelerators, gamma rays from the Gamma Knife, and less frequently, charged particles such as protons produced by cyclotrons have all been utilized. In controlled studies in patients with tumors up to 3 cm in diameter, SRS produces local control rates of approximately 70 percent at one year following treatment [38]. This rate improves to up to 90 percent when adjunctive WBRT is provided. Although traditionally used to treat a limited number of tumors, prospective nonrandomized data in patients with newly diagnosed brain metastases suggest that up to 10 tumors with a total cumulative volume ≤ 15 mL may be treated in a single session with similar efficacy and no increase in toxicity [39].

In patients with ES-SCLC who did not respond to the chemotherapy may benefit from palliative RT to symptomatic metastatic sites. The most common thoracic symptoms that need palliation are pain, cough, hemoptysis, post-obstructive pneumonia, superior vena cava syndrome. Additionally painful bone metastases may benefit from palliative RT.

**Normal tissue toxicity**

The risk and severity of radiation toxicity in normal tissue are related to the dose and volume irradiated, as well as the functional organization of the organ at risk. In
The toxicity of the thoracic irradiation

Lung: In patients with lung cancer, clinical pneumonitis occurred in 5 to 20 percent of patients, while radiographic abnormalities were present in 66 percent. It is unclear to what extent the latter were due to irradiation versus tumor. Radiation pneumonitis may occur during fractionated treatment or up to 18 months afterward, with a peak incidence at 2-6 months [40].

Radiation-Induced Lung Injury (RILI) which is also named as “radiation pneumonopathy” is a continuous process and regarded as the result of an abnormal healing response. Subclinical early damage in pneumocytes type I progress to an acute interstitial inflammation at 6-12 weeks after the onset of Radio Therapy (RT) and further to lung fibrosis after many months and years. Inflammation is an essential part of the normal wound healing process [42-44]. Clinically radiation-induced lung injury is typically divided into two phases: pneumonitis and fibrosis. The fibrotic phase tends to manifest > 3 months after treatment. Fibrosis is part of the wound-healing process. Therefore radiation fibrosis is a form of chronic lung damage that usually evolves over 4-24 months after irradiation [44].

Symptoms caused by acute radiation pneumonitis usually develop approximately four to twelve weeks following irradiation, whereas symptoms of late or fibrotic radiation pneumonitis develop after six to twelve month. The most common Clinical presentation includes a persistent non-productive cough, dyspnoea, low-grade fever, and fatigue. Patient may experience a chest pain that may be pleuritic or subternal and can represent pleuritis, esophageal pathology, or rib fracture. Malaise and weight loss may be observed [43]. Chest x-ray or Computed Tomography (CT) scan may be normal, or depending on the time course, there may be ground glass opacification (within 2 to 6 months), patchy consolidation 4 to 12 months), or fibrosis (10 months or more); that loosely corresponds to the radiation field [40,45].

Many factors including method of irradiation, volume of irradiated lung, dosage of irradiation, time-dose factor, and the use of concurrent chemotherapy may affect the development of radiation-induced lung disease [45]. Several patient related factors also impact the risk of radiation-induced lung disease. Such as older age, continue to smoke during RT may effect negatively to radiation pneumonitis [40].

QUANTEC data suggests that the risk of radiation pneumonitis is < 20% when the mean lung dose is less than approximately 20 Gy with conventional fractionation [46]. With regard to Vdose threshold models, radiation pneumonitis risk is < 20% for Vd50 < 30-35 Gy; or V5 < 60% with conventional fractionation [40,46].

Esophagus: The esophagus as a central serial organ with radiosensitive mucosa can suffer from side-effects after RT for the treatment of cancers of lungs and bronchi. Acute esophagitis is often the most prominent symptom during fractionated RT for thoracic malignancy, leading to inpatient admissions, dehydration, weight loss, and treatment interruption. On the other hand late esophageal toxicity may include stricture, perforation, or fistula formation [40].

Irradiation-induced cell death affects especially cells with rapid cell turnover. Thus, during an irradiation course the renewal of the surface of the esophageal mucosa is impaired and hence prone to damage and development of esophagitis. Early morphologic radiation induced alterations comprise nuclear hyperchromasias or denudation, focal basal epithelial cell necrosis, epithelial swelling and erosions [47] or edema and petechiae in the lamina propria and in the submucosa. Patients with odynophagia or dysphagia as AET were observed to have discrete ulcers, granular mucosa and a narrowed lumen of the gullet. Additionally, the damaged mucosa is vulnerable for superinfection or growth of candida. The described radiation induced morphological changes can lead to abnormal peristalsis, typically beginning in the cranial irradiated aspects of the organ, passing down to the lower sphincter [47,48]. Abnormal motility has been seen for up to more than a decade after treatment [48-50].

Dysphagia is the main clinical symptom of radiation induced esophagitis and can be associated with severe pain [50]. Grade 3 or garter acute esophagitis occurs in
15–25% of patients during or shortly after irradiation and may lead hospitalization and unwanted treatment breaks [40].

Esophageal toxicity is related to both dose and volume of irradiation. Accelerated fractionation, older patient age, the use of concurrent chemotherapy may also increase the risk of acute esophagitis [40]. For conventional thoracic RT the volume of the esophagus receiving 40 or 50 Gy (V40, V50) is commonly accepted as a guidance level to estimate the risk of esophagitis [50]. However the relationship between esophageal side effects and treatment outcome for patients with esophageal cancer needs better understanding.

Heart: The majority of the radiation-induced cardiovascular disease has been reported in patients who previously treated with thoracic RT for Hodgkin’s disease and breast cancer. Estimated relative risk of fatal cardiovascular events after RT for Hodgkin’s disease and left-sided breast cancer range between 2.2 and 7.2 and 1.0 to 2.2, respectively, compared to healthy controls. Risk is lifelong and absolute risk appears to increase with length of time since exposure. Radiation-associated cardiovascular toxicity may in fact be progressive [51]. Reported toxicities include acute pericarditis, which can progress to chronic pericardial fibrosis, effusion, or rarely constrictive pericarditis. Valvular abnormalities were also reported [40,51].

Numerous studies of radiation-induced toxicity show that endothelial cell injury is the key point in most tissues even though the endothelial cells compromise only a minor fraction of cardiac cells [52]. The sequence of endothelial injury, cell detachment, thrombosis and fibrosis result in significant tissue injury that often limits radiation oncologist in attempting to deliver curative doses to a nearby tumor. Steward and Fajardo have demonstrated that damage to the myocardium develops through three phases of injury [53]. The acute inflammation phase occurs about 6 hours after RT and a neutrophilic infiltrate develops involving all layers of heart. The second phase also known as latent phase in which a slight progressive fibrosis begins about 2 days after exposure. However electron microscopy of the myocardial capillary endothelial cells demonstrates progressive damage leading to obstruction of the lumen and thrombi of fibrin and platelets. Though healthy endothelial cell replication in the vicinity occurred, it is generally inadequate and an inevitable ischemia leads to progressive fibrosis. Animals begin to die at approximately 70th day due to extensive fibrosis. The hallmark of this late stage is extensive fibrosis.

Both the treatment related factors including the dose, the volume of heart irradiated; and the patient related factors including hypertension, diabetes, obesity and genetic predisposition may affect the risk of radiation-induced cardiac toxicity. The risk of pericardial toxicity has been correlated with treatment of > 50% of the heart contour in 2-dimensional planning and to the volume of ≥ 30 Gy in 3-dimensional planning. The risk of pericarditis can be minimized by keeping the mean pericardial dose < 26 Gy or the pericardial V30 < 46% [40].

Brachial plexus: Radiation brachial plexopathy is a rare condition which is therefore poorly described. There are case reports of an early transient plexopathy that occurs during or within weeks to months of radiation. On the other hand late radiation plexopathy manifests years after radiation to the supravacular area with hypoesthesia, paresthesia, and weakness of the affected arm or shoulder. It may progress to total paralysis of the affected arm with severe pain Late plexopathy is rare in patients who have received ≤ 60 Gy [40].

The toxicity of the brain irradiation: Even if there are strong evidence suggesting that PCI reduces the incidence of brain metastases and increases overall survival in SCLC patients, its indications should be considered in the light of its potential neurotoxicity. Acute toxicities associated with PCI include fatigue, alopecia, scalp erythema, and to a lesser extent, headaches and low-grade nausea, all of which are usually self-limited. These reactions are usually treated symptomatically by anti-edema therapy with corticosteroids or Glyceol Fatigue and alopecia are the most prevalent short-term toxicities [54,55]. Long-term toxicity is of concern, as sequela including memory loss, intellectual impairment or even dementia, ataxia, or seizures have been reported in retrospective studies attributed to PCI. However most of these are retrospectively designed studies conducted on limited number of patients. Therefore it is difficult to conclude whether PCI alone is responsible for the observed neurological sequela [54].

The frequency and severity of chronic toxicities associated with PCI are still unclear. Since the patients undergoing PCI have an improvement in overall survival, they are more likely to develop chronic neurotoxicity. Tai, et al. designed a retrospective study in order to investigate the therapeutic usefulness and cost-effectiveness of PCI in patients with LS-SCLC who had achieved a complete remission [55]. Their results suggested that the patients who received PCI a significant improvement in mean quality time without symptoms and toxicity. In a similar analysis, qualitatively life expectancy adjusted quality and survival were evaluated. PCI offers a benefit over no-PCI [56]. The results of these analyses suggested benefit of PCI despite chronic toxicity. However, it is necessary to design clinical trials with the specific aim to adequately answer the question of benefit vs. neurotoxicity and quality of life in patients receiving PCI [1].
Mounting evidence suggests that radiation-induced damage to the hippocampus plays a role in neurocognitive decline for patients receiving WBRT; therefore novel strategies to improve radiation-induced neurocognitive function are warranted. Hippocampal Avoidance Whole-Brain Radiotherapy (HA-WBRT) has been proposed to reduce the putative neurocognitive deficits by limiting the dose to the hippocampus. Two recent clinical trials, phase III RTOG 0614 and phase II RTOG 0933, showed some effectiveness of Memantine and IMRT planning for hippocampus sparing, among patients receiving WBRT [57,58]. The precise mechanisms by which WBRT leads to cognitive decline are largely unknown. Ablation of hippocampal neurogenesis and radiation-induced vascular damage in the brain [59] have been proposed as potential mechanisms that may play roles in the development of late delayed radiation-induced brain injury. Radiation Therapy Oncology Group (RTOG) 0614 was a phase III trial [57] that considered the role of Memantine, an N-Methyl D-Aspartate (NMDA) antagonist, which is traditionally used for dementia, including vascular dementia, while RTOG 0933 was a phase II single arm trial that considered the role of avoiding the hippocampus on cognitive decline [58]. The majority of surveyed radiation oncologists in the US do not use Memantine, or IMRT planning for hippocampus sparing in patients receiving WBRT. Further validation of the hippocampus sparing concept in a phase III trial was supported, before adopting it in routine clinical practice [59]. There are ongoing studies including NCT01797159 about the role of hippocampal prophylactic cranial Irradiation for small cell lung cancer. As treatment for SCLC becomes more successful, the potential for long-term neurotoxicity due to PCI will be more relevant. Research efforts to minimize the neurotoxicity of PCI have included twice daily fractionation (1.5 Gy twice-daily to 30 to 36 Gy), hippocampal-sparing whole brain radiotherapy, and the use of alternative systemic agents [34,60-62].

Conclusion

RT has an important role in the management of SCLC patients. In LS-SCLC both thoracic RT and PCI improves local control as well as overall survival. In ES-SCLC patients thoracic RT becoming more and more important, since growing evidence suggests that the use of consolidation thoracic RT after first-line chemotherapy in the selected patients also improve both local control and overall survival. The use of PCI in ES-SCLC patients who have any degree of response to systemic therapy decreases the incidence of symptomatic brain metastases. Ongoing trials seek to better define the dose and fractionation of thoracic RT in both ES-SCLC and LS-SCLC, and the role of consolidation thoracic RT in ES-SCLC patients.


36. Seto T, Takahashi T, Yamanaka T, et al. (2014) Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. J Clin Oncol 32: 5S.


